CogstateASX:CGS +0.72%77 Buyback Yield % is 0.72 as of Jun. 29, 2026. GuruFocus rates ASX:CGS with a GF Score™ of 77/100 and a GF Value™ of A$2.05 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 271 Healthcare Providers & Services companies, Cogstate ranks better than 69% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Cogstate's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CGS vs VEEV, BTSG, TEM: Buyback Yield % Comparison
For the Health Information Services subindustry, Cogstate's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogstate Buyback Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cogstate's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Cogstate's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cogstate (ASX:CGS) has a Buyback Yield % of 0.72 as of Jun. 29, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cogstate and its competitors. According to the industry distribution chart, Cogstate ranks #84 out of 271 companies in the Healthcare Providers & Services industry, placing it in the top 31%.
Is Cogstate's Buyback Yield % too high?
Cogstate's current Buyback Yield % is 0.72. Based on the distribution chart, Cogstate ranks #84 out of 271 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Cogstate has a GF Score™ of 77/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cogstate's Buyback Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Cogstate ranks #84 out of 271 companies for Buyback Yield %. This puts Cogstate in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Healthcare Providers & Services company?
A good Buyback Yield % depends on the Healthcare Providers & Services industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Cogstate and its competitors. Cogstate's current Buyback Yield % is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogstate stock overvalued right now?
Based on GuruFocus' analysis, Cogstate (ASX:CGS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$2.05, compared to a current price of A$2.78 — trading 35.6% above its estimated fair value. The current Buyback Yield % is 0.72. Cogstate's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Cogstate (ASX:CGS), the current Buyback Yield % is 0.72 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cogstate (ASX:CGS) Overvalued in 2026?
Based on GuruFocus' analysis, Cogstate stock appears to be overvalued.
The current stock price of A$2.78 is trading 35.6% above its estimated GF Value™ of A$2.05.
GuruFocus considers Cogstate to be Significantly Overvalued.
Key valuation signals for ASX:CGS:
Buyback Yield %: 0.72
GF Value™: A$2.05 vs. price of A$2.78 (35.6% above fair value)
No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score
Get the complete analysis for ASX:CGS
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CGS has been successfully added to your 
